Evidence map›Paper›PMID 39936439›Full record

ArticleRecent patents on anti-cancer drug discovery2026

The Prognostic Role of Interferon Gamma-inducible Protein 30 in Clear Cell Renal Cell Carcinoma with Immune Infiltrates.

Wu Xu, Taihong Wu, Yufeng Liu, Yang Luo, Dawei Liu, Lingfei Yan, Qing Li, Tao Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Recent patents on anti-cancer drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wu XuDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.
Taihong WuDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.
Yufeng LiuDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.
Yang LuoDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.
Dawei LiuDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.
Lingfei YanDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.
Qing LiDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.
Tao WangDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, No.566, Congcheng Avenue, Guangzhou, Guangdong, 510900, China.

Funding

Characteristic Innovation Program of Ordinary Colleges and Universities of Guangdong Province of China 2024KTSCX076Medical Scientific Research Foundation of Guangdong Province of China A2023463President Foundation of The Fifth Affiliated Hospital, Southern Medical University YZ2022ZX09, YZ2020MS06
6 · The paper itself

Abstract

backgroundRecent research has demonstrated the significance of Interferon Gamma- Inducible Protein 30 (IFI30), an interferon gamma-induced protein, in the immune response to cancerous growths. However, the relationship between IFI30 expression levels, patient prognosis, and tumor-infiltrating lymphocytes in clear cell renal cell carcinoma (ccRCC) remains inadequately defined.

methodsTo ascertain the potential link between IFI30 expression, clinical data, and overall survival (OS) in ccRCC patients, we employed diverse databases, which include TCGA, Gene Expression Profiling Interaction Analysis (GEPIA), and UALCAN. Furthermore, an in-depth analysis of the link between tumor-infiltrating immune cells (TIIC) and IFI30 was carried out using the TIMER, GEPIA, and TISIDB databases. Immunohistochemistry (IHC) was utilized to identify the IFI30 and PD-1 expression levels in a tissue microarray. Patents about molecular classification and drugs in ccRCC were reviewed through Worldwide Espacenet®.

resultsThe expression of IFI30 demonstrated a strong association with sample type, lymph node stage, tumor grade, and cancer stage. Elevated IFI30 expression was linked to unfavorable Disease- Specific Survival (DSS) and Overall Survival (OS) outcomes (p <0.01). Furthermore, overexpression of IFI30 was strongly linked to immunomodulatory molecules, chemokines, and increased infiltration of regulatory T cells (Tregs), natural killer (NK) CD56 cells, T helper 1 (Th1) cells, cytotoxic T cells, and T helper cells. IHC analysis confirmed a robust correlation between IFI30 and PD-1 expression.

conclusionIFI30 is a prognostic biomarker for ccRCC patients. Targeting IFI30 may provide new strategies for cancer therapy and improve the prognosis of ccRCC patients.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsLymphocytes, Tumor-InfiltratingHumansPrognosisBiomarkers, Tumorclear cell renal cell carcinomaIFI30immunohistochemistryPD-1prognosistumor immune microenvironment

Identifiers

PMID39936439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.